Recurrence rates at the site of excision in several studies have been ~15% although rates as low as 1% have been reported by specialized centers. These tumors do not metastasize (i.e. spread to distant tissues) and have an excellent long-term prognosis. See also
List of cutaneous conditions
Skin lesion
Hamartoma


== References ==
These astrocytes have an unhealthily large amount of GFAP that affects astrocyte formation and function. Diagnosis
The degeneration of white matter, which shows the degeneration of myelin, can be seen in a basic MRI and used to diagnose leukodystrophies of all types. T-1 and T-2 weighted FLAIR images are the most useful. FLAIR stands for fluid-attenuated inversion recovery. Electrophysiological and other kinds of laboratory testing can also be done. In particular, nerve conduction velocity is looked at to distinguish between leukodystrophy and other demyelinating diseases, as well as to distinguish between individual leukodystrophies. For example, individuals with X-ALD have normal conduction velocities, while those with Krabbe disease or metachromatic leukodystrophy have abnormalities in their conduction velocities. Next generation multigene sequencing panels for undifferentiated leukodystrophy can now be offered for rapid molecular diagnosis after appropriate genetic counselling. Types
Specific types of leukodystrophies include the following with their respective ICD-10 codes when available:
(E71.3) Adrenomyeloneuropathy
(E75.2) Alexander disease
(E75.5) Cerebrotendineous xanthomatosis
Hereditary CNS demyelinating disease
(E75.2) Krabbe disease
(E75.2) Metachromatic leukodystrophy
(E75.2) Pelizaeus–Merzbacher disease
(E75.2) Canavan disease
(E75.2) Hypomyelinating leukodystrophy type 7 (4H syndrome)
(G93.49) Leukoencephalopathy with vanishing white matter
(E71.3) Adrenoleukodystrophy
(G60.1) Refsum disease

Treatment
With many different types of leukodystrophies and causes, treatment therapies vary for each type. Many studies and clinical trials are in progress to find treatment and therapies for each of the different leukodystrophies. Stem cell transplants and gene therapy appear to be the most promising in treating all leukodystrophies providing it is done as early as possible. For hypomyelinating leukodystrophies, therapeutic research into cell-based therapies appears promising.